Triveni Bio raised $65 million in a Series C round co-led by Ascenta and Henderson Investors.
- Amount
- $65M
- Stage
- Series C
- Announced
- 17 June 2026
- Leads
- Ascenta Capital, Janus Henderson Investors
- Other investors
- Deep Track Capital
- Use of funds
- Extend the scope and rigor of TRIV-573 clinical development, including a Phase 2 atopic dermatitis proof-of-concept study.
- Checked
- Amount and date matched across 3 press sources